ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 172 filers reported holding ARENA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $140,000 | -11.4% | 2,050 | -0.5% | 0.00% | -33.3% |
| Q4 2020 | $158,000 | -28.8% | 2,060 | -30.5% | 0.01% | -40.0% |
| Q3 2020 | $222,000 | +37.9% | 2,966 | -22.7% | 0.01% | -9.1% |
| Q1 2020 | $161,000 | +18.4% | 3,835 | +28.0% | 0.01% | +57.1% |
| Q4 2019 | $136,000 | -28.4% | 2,995 | -7.5% | 0.01% | -41.7% |
| Q3 2019 | $190,000 | 0.0% | 3,239 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $190,000 | +8.6% | 3,239 | -17.1% | 0.01% | 0.0% |
| Q1 2019 | $175,000 | +8.7% | 3,909 | -5.7% | 0.01% | -14.3% |
| Q4 2018 | $161,000 | -21.5% | 4,144 | -7.0% | 0.01% | -6.7% |
| Q3 2018 | $205,000 | +38.5% | 4,454 | +20.0% | 0.02% | +36.4% |
| Q2 2018 | $148,000 | +5.0% | 3,711 | +4.2% | 0.01% | 0.0% |
| Q1 2018 | $141,000 | +22.6% | 3,561 | +5.3% | 0.01% | +10.0% |
| Q4 2017 | $115,000 | +27.8% | 3,381 | -4.7% | 0.01% | 0.0% |
| Q3 2017 | $90,000 | +76.5% | 3,548 | +17.2% | 0.01% | +42.9% |
| Q2 2017 | $51,000 | – | 3,028 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 163,133 | $7,467,000 | 4.14% |
| PFM Health Sciences, LP | 2,271,536 | $103,968,000 | 3.07% |
| Partner Investment Management, L.P. | 28,877 | $1,322,000 | 2.26% |
| Atika Capital Management LLC | 181,000 | $8,284,000 | 1.74% |
| DAFNA Capital Management LLC | 93,942 | $4,300,000 | 1.62% |
| Asymmetry Capital Management, L.P. | 16,272 | $745,000 | 1.60% |
| First Light Asset Management, LLC | 190,838 | $8,735,000 | 1.32% |
| Perceptive Advisors | 953,129 | $43,624,000 | 1.18% |
| Rhenman & Partners Asset Management AB | 155,000 | $7,094,000 | 0.89% |
| Opus Point Partners Management, LLC | 9,770 | $447,000 | 0.81% |